Literature DB >> 33900435

A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?

Alessandro Leonetti1,2,3, Daniela Carbone3,4, Alessandro Gregori3, Marcello Tiseo1,2, Godefridus J Peters3,5, Dongmei Deng6, Elisa Giovannetti7,8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33900435     DOI： 10.1007/s00432-021-03647-x

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


× No keyword cloud information.
  9 in total

1.  The microbiome of pancreatic cancer: from molecular diagnostics to new therapeutic approaches to overcome chemoresistance caused by metabolic inactivation of gemcitabine.

Authors:  Arthur T F Choy; Ilaria Carnevale; Stefano Coppola; Laura L Meijer; Geert Kazemier; Egija Zaura; Dongmei Deng; Elisa Giovannetti
Journal:  Expert Rev Mol Diagn       Date:  2018-11-09       Impact factor: 5.225

Review 2.  Pharmacogenetics of treatments for pancreatic cancer.

Authors:  Btissame El Hassouni; Giovanna Li Petri; Daniel S K Liu; Stella Cascioferro; Barbara Parrino; Waqar Hassan; Patrizia Diana; Asif Ali; Adam E Frampton; Elisa Giovannetti
Journal:  Expert Opin Drug Metab Toxicol       Date:  2019-05-24       Impact factor: 4.481

3.  Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.

Authors:  Leore T Geller; Michal Barzily-Rokni; Tal Danino; Oliver H Jonas; Noam Shental; Deborah Nejman; Nancy Gavert; Yaara Zwang; Zachary A Cooper; Kevin Shee; Christoph A Thaiss; Alexandre Reuben; Jonathan Livny; Roi Avraham; Dennie T Frederick; Matteo Ligorio; Kelly Chatman; Stephen E Johnston; Carrie M Mosher; Alexander Brandis; Garold Fuks; Candice Gurbatri; Vancheswaran Gopalakrishnan; Michael Kim; Mark W Hurd; Matthew Katz; Jason Fleming; Anirban Maitra; David A Smith; Matt Skalak; Jeffrey Bu; Monia Michaud; Sunia A Trauger; Iris Barshack; Talia Golan; Judith Sandbank; Keith T Flaherty; Anna Mandinova; Wendy S Garrett; Sarah P Thayer; Cristina R Ferrone; Curtis Huttenhower; Sangeeta N Bhatia; Dirk Gevers; Jennifer A Wargo; Todd R Golub; Ravid Straussman
Journal:  Science       Date:  2017-09-15       Impact factor: 47.728

4.  [Temporary peritoneal dialysis in the treatment of acute kidney failure].

Authors:  F Quadri; G Keusch; U Binswanger
Journal:  Schweiz Rundsch Med Prax       Date:  1983-07-05

5.  Impact of smoking status on EGFR-TKI efficacy for advanced non-small-cell lung cancer in EGFR mutants: a meta-analysis.

Authors:  Yaxiong Zhang; Shiyang Kang; Wenfeng Fang; Shaodong Hong; Wenhua Liang; Yue Yan; Tao Qin; Yanna Tang; Jin Sheng; Li Zhang
Journal:  Clin Lung Cancer       Date:  2014-10-02       Impact factor: 4.785

Review 6.  RX-3117 (fluorocyclopentenyl cytosine): a novel specific antimetabolite for selective cancer treatment.

Authors:  Beatrice Balboni; Btissame El Hassouni; Richard J Honeywell; Dzjemma Sarkisjan; Elisa Giovannetti; Julie Poore; Callie Heaton; Christine Peterson; Ely Benaim; Young B Lee; Deog J Kim; Godefridus J Peters
Journal:  Expert Opin Investig Drugs       Date:  2019-03-16       Impact factor: 6.206

7.  A multicenter clinical study: personalized medication for advanced gastrointestinal carcinomas with the guidance of patient-derived tumor xenograft (PDTX).

Authors:  Yuan Cheng; Shu-Kui Qin; Jin Li; Guang-Hai Dai; Bai-Yong Shen; Jie-Er Ying; Yi Ba; Han Liang; Xin-Bo Wang; Ye Xu; Lin Zhou; Ke-Feng Ding; Yan-Ru Qin; Shu-Jun Yang; Wen-Xian Guan; Hui Zheng; Qian Wang; Hang Song; Yan-Ping Zhu
Journal:  J Cancer Res Clin Oncol       Date:  2021-04-17       Impact factor: 4.553

Review 8.  Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer.

Authors:  Simon Vyse; Paul H Huang
Journal:  Signal Transduct Target Ther       Date:  2019-03-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.